TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00983268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg taken by mouth on the days of radiation only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to remove tumor
Description: Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
Study: NCT02488655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study: NCT03711279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 plus Apatinib
Description: SHR-1210 200 mg q3w+ Apatinib 500 mg qd
Study: NCT01066962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)
Study: NCT05129917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gojinsen® drinks
Description: consume 1 sachet per day for 14 day
Study: NCT03711279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADM plus IFO or IFO alone
Description: ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
Study: NCT02285907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient and Fiber Matched BEEF
Description: The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient and Fiber Matched SOY
Description: The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving Size Matched BEEF
Description: The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving Size Matched SOY
Description: The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
Study: NCT01596465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Study using MP3 Player
Description: Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lecture
Description: Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
Study: NCT00904085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone IR
Description: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxymorphone IR
Description: 5 mg
Study: NCT02073214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Standard treatment plus probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard treatment plus placebo
Study: NCT00417885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg, oral, daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 37.5 mg, oral, continuous dosing, daily
Study: NCT03659942

Intervention type: OTHER
Intervention: CAST questionnaire
Description: the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
Study: NCT02859233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lack of hyperhydration
Study: NCT04424238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-health management
Description: Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
Study: NCT04037319

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 Hour Holter Monitor
Description: 24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
Study: NCT01223014

Intervention type: DRUG
Intervention: AZD2423
Description: AZD2423
Study: NCT03823794

Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only
Study: NCT01958775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: single subcutaneous dose of 1500mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04222569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-piece
Description: Spontaneous breath trial with a T-piece
Study: NCT04249440

Intervention type: PROCEDURE
Intervention: Preoperative systemic treatment
Description: neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
Study: NCT01771445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-1Ra
Description: 100mg, s.c, once only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg, s.c., once only
Study: NCT02553408

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Precision Neo-Meter
Description: Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
Study: NCT01675362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant group
Description: They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers
Description: They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blocker group
Description: They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will receive placebo
Study: NCT03437707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ibuprofen
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study: NCT02152774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor
Study: NCT01946126

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this study.
Study: NCT03743688

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine Recipients
Description: 0.5 mL intramuscular injection
Study: NCT03136861

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: anti IL-17a monoclonal antibody
Study: NCT03778385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
Study: NCT06089902

Intervention type: PROCEDURE
Intervention: unroofing or other surgery if needed
Description: unroofing of coronary artery

Intervention type: PROCEDURE
Intervention: unroofing or other surgery if needed
Description: unroofing of coronary artery
Study: NCT03136861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457
Study: NCT01828411

Intervention type: DEVICE
Intervention: Transpharyngeal ultrasonography
Description: Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.

Intervention type: DEVICE
Intervention: Transpharyngeal ultrasonography
Description: Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
Study: NCT01668017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study: NCT03136861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457
Study: NCT00982527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline continuous infusion during cardiopulmonary by pass at 1 ml/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline continuous infusion during cardiopulmonary by pass at 1 ml/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Study: NCT01668017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study: NCT01828411

Intervention type: DEVICE
Intervention: Duplex sonography
Description: Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.

Intervention type: DEVICE
Intervention: Duplex sonography
Description: Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
Study: NCT01205477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL
Description: Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Study: NCT01571856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cornstarch powder diluted in distilled water, dosage 2.5 ml per day
Study: NCT01729208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Focus Soft Contact Lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single Vision Soft Contact Lens
Study: NCT01613430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed Educational Materials (PEM)
Description: Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
Study: NCT00982527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Study: NCT00584909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin combination
Description: Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
Study: NCT00689416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 40 mg, tablet, once daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg, tablet, once daily for 3 months
Study: NCT04353856

Intervention type: OTHER
Intervention: quality of life assessment
Description: quality of life assessment using the EQ5D questionnaire once a month
Study: NCT01668017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study: NCT02763657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scanning
Description: All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
Study: NCT02613767

Intervention type: OTHER
Intervention: Protein meal
Description: Ingestion of protein

Intervention type: OTHER
Intervention: Protein meal
Description: Ingestion of protein

Intervention type: OTHER
Intervention: Protein meal
Description: Ingestion of protein

Intervention type: OTHER
Intervention: L-[ring 13C6]Phenylalanine infusion
Description: experimental method for determining protein synthesis rates

Intervention type: OTHER
Intervention: L-[ring 13C6]Phenylalanine infusion
Description: experimental method for determining protein synthesis rates
Study: NCT03572790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1mg prucalopride capsule, once daily for seven days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo capsule, once daily for seven days
Study: NCT02025439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Study: NCT04148573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 1
Description: 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 2
Description: 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 3
Description: 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO - 4
Description: 3 times a day
Study: NCT02025439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Study: NCT02297672

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stranded palladium seed interstitial implant
Description: Interstitial implantation of stranded palladium 103 seeds in seroma with a margin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 dimensional breast ultrasound
Description: guidance of placement of interstitial needles in breast

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT)
Description: Breast CT for planning and assessing interstitial implantation of radioactive seeds
Study: NCT03053466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-501
Description: Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle.
Study: NCT03854630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.